Nektar Therapeutics (NKTR) Change in Receivables (2010 - 2024)

Nektar Therapeutics' Change in Receivables history runs 15 years deep, the most recent figure standing at $2.2 million for Q4 2024.

• On a quarterly basis, Change in Receivables rose 320.62% year-over-year to $2.2 million in Q4 2024; TTM through Sep 2025 was $2.2 million, a 1494.94% increase from a year earlier, with the FY2024 full-year figure at $3.0 million, up 163.76% from the prior year.
• Change in Receivables grew to $2.2 million in Q4 2024 per NKTR's latest filing, from $850000.0 in the prior quarter.
• Across five years, Change in Receivables topped out at $7.7 million in Q1 2022 and bottomed at -$20.2 million in Q2 2022.
• The 5-year median for Change in Receivables is -$642000.0 (2021), against an average of -$1.6 million.
• Across the five-year window, Change in Receivables surged 1739.18% in 2020 and sank 6992.63% in 2022, its largest moves.
• Year by year, Change in Receivables stood at -$8.0 million in 2020, then jumped by 68.87% to -$2.5 million in 2021, then sank by 121.86% to -$5.6 million in 2022, then soared by 82.0% to -$999000.0 in 2023, then jumped by 320.62% to $2.2 million in 2024.
• Per Business Quant, the three latest NKTR Change in Receivables figures stand at $2.2 million (Q4 2024), $850000.0 (Q3 2024), and -$2.4 million (Q2 2024).